Milad Mohammadi

Milad Mohammadi

Auto-generated profile, based on publicly available information

Milad Mohammadi

Institute for Pharmacology and Toxicology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany; Integrative Neuroscience Program, Otto-von-Guericke University Magdeburg, Magdeburg, Germany

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BOBeatrice Oehler
Beatrice Oehler
KKKatrin Kistner
Katrin Kistner
CMCorinna Martin
Corinna Martin
JSJürgen Schiller
Jürgen Schiller
RMRafaela Mayer
Rafaela Mayer
HRHeike L. Rittner
Heike L. Rittner
Phospholipids occurring in cell membranes and lipoproteins are converted into oxidized phospholipids (OxPL) by oxidative stress promoting atherosclerotic plaque formation. Here, OxPL were characterized as novel targets in acute and chronic inflammatory pain. Oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (OxPAPC) and its derivatives were identified in inflamed tissue by mass spectrometry and binding assays. They elicited calcium influx, hyperalgesia and induced pro-nociceptive peptide release. Genetic, pharmacological and mass spectrometric evidence in vivo as well as in vitro confirmed the role of transient receptor potential channels (TRPA1 and TRPV1) as OxPAPC targets. Treatment with the monoclonal antibody E06 or with apolipoprotein A-I mimetic peptide D-4F, capturing OxPAPC in atherosclerosis, prevented inflammatory hyperalgesia, and in vitro TRPA1 activation. Administration of D-4F or E06 to rats profoundly ameliorated mechanical hyperalgesia and inflammation in collagen-induced arthritis. These data reveal a clinically relevant role for OxPAPC in inflammation offering therapy for acute and chronic inflammatory pain treatment by scavenging OxPAPC.

16 September 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HKHashem Khanbabaei
Hashem Khanbabaei
SESaeedeh Ebrahim
Saeedeh Ebrahim
JGJuan Luis García-Rodríguez
Juan Luis García-Rodríguez
ZGZahra Ghasemi
Zahra Ghasemi
HPHossein Pourghadamyari
Hossein Pourghadamyari
LKLasse Kristensen
Lasse Kristensen
Epithelial-mesenchymal transition (EMT) is a fundamental process for embryonic development during which epithelial cells acquire mesenchymal characteristics, and the underlying mechanisms confer malignant features to carcinoma cells such as dissemination throughout the organism and resistance to anticancer treatments. During the past decades, an entire class of molecules, called non-coding RNA (ncRNA), has been characterized as a key regulator of almost every cellular process, including EMT. Like protein-coding genes, ncRNAs can be deregulated in cancer, acting as oncogenes or tumor suppressors. The various forms of ncRNAs, including microRNAs, PIWI-interacting RNAs, small nucleolar RNAs, transfer RNA-derived RNA fragments, long non-coding RNAs, and circular RNAs can orchestrate the complex regulatory networks of EMT at multiple levels. Understanding the molecular mechanism underlying ncRNAs in EMT can provide fundamental insights into cancer metastasis and may lead to novel therapeutic approaches. In this review, we describe recent advances in the understanding of ncRNAs in EMT and provide an overview of recent ncRNA applications in the clinic.

11 October 2022 in The EMBO Journal
Verified
Journal Article
Open access
MOMelina Overhoff
Melina Overhoff
FTFrederik Tellkamp
Frederik Tellkamp
SHSimon Hess
Simon Hess
MTMarianna Tolve
Marianna Tolve
JTJanine Tutas
Janine Tutas
NKNatalia Kononenko
Natalia Kononenko
Autophagy provides nutrients during starvation and eliminates detrimental cellular components. However, accumulating evidence indicates that autophagy is not merely a housekeeping process. Here, by combining mouse models of neuron‐specific ATG5 deficiency in either excitatory or inhibitory neurons with quantitative proteomics, high‐content microscopy, and live‐imaging approaches, we show that autophagy protein ATG5 functions in neurons to regulate cAMP‐dependent protein kinase A (PKA)‐mediated phosphorylation of a synapse‐confined proteome. This function of ATG5 is independent of bulk turnover of synaptic proteins and requires the targeting of PKA inhibitory R1 subunits to autophagosomes. Neuronal loss of ATG5 causes synaptic accumulation of PKA‐R1, which sequesters the PKA catalytic subunit and diminishes cAMP/PKA‐dependent phosphorylation of postsynaptic cytoskeletal proteins that mediate AMPAR trafficking. Furthermore, ATG5 deletion in glutamatergic neurons augments AMPAR‐dependent excitatory neurotransmission and causes the appearance of spontaneous recurrent seizures in mice. Our findings identify a novel role of autophagy in regulating PKA signaling at glutamatergic synapses and suggest the PKA as a target for restoration of synaptic function in neurodegenerative conditions with autophagy dysfunction.

1 October 2014 in Behavioural Brain Research
Verified
Journal Article
Closed access
MMMilad Mohammadi
Milad Mohammadi
JBJorge R. Bergado-Acosta
Jorge R. Bergado-Acosta
Markus FendtMarkus Fendt
Markus Fendt

3 August 2017 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
BOBeatrice Oehler
Beatrice Oehler
MMMilad Mohammadi
Milad Mohammadi
CVCristina Perpiñá Viciano
Cristina Perpiñá Viciano
DHDagmar Hackel
Dagmar Hackel
CHCarsten Hoffmann
Carsten Hoffmann
HRHeike L. Rittner
Heike L. Rittner
Antinociceptive pathways are activated in the periphery in inflammatory pain, for instance resolvins and opioid peptides. Resolvins are biosynthesized from omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid and docosahexaenoic acid. Resolvin D1 (RvD1) and resolvin E1 (RvE1) initiate the resolution of inflammation and control of hypersensitivity via induction of anti-inflammatory signaling cascades. RvD1 binds to lipoxin A4/annexin-A1 receptor/formyl-peptide receptor 2 (ALX/FPR2), RvE1 to chemerin receptor 23 (ChemR23). Antinociception of RvD1 is mediated by interaction with transient receptor potential channels ankyrin 1 (TRPA1). Endogenous opioid peptides are synthesized and released from leukocytes in the tissue and bind to opioid receptors on nociceptor terminals. Here, we further explored peripheral mechanisms of RvD1 and chemerin (Chem), the ligand of ChemR23, in complete Freund’s adjuvant (CFA)-induced hindpaw inflammation in male Wistar rats. RvD1 and Chem ameliorated CFA-induced hypersensitivity in early and late inflammatory phases. This was prevented by peripheral blockade of the µ-opioid peptide receptor (MOR) using low dose local naloxone or by local injection of anti-β-endorphin and anti-met-enkephalin antibodies. Naloxone also hindered antinociception by the TRPA1 inhibitor HC-030031. RvD1 did not simulate the release of β-endorphin from macrophages and neutrophils, nor did RvD1 itself activate G-proteins coupled MOR or initiate β-arrestin recruitment to the membrane. TRPA1 blockade by HC-030031 in inflammation in vivo as well as inhibition of the TRPA1-mediated calcium influx in dorsal root ganglia neurons in vitro was hampered by naloxone. Peripheral application of naloxone alone in vivo already lowered mechanical nociceptive thresholds. Therefore, either a perturbation of the balance of endogenous pro- and antinociceptive mechanisms in early and late inflammation, or an interaction of TRPA1 and opioid receptors weaken the antinociceptive potency of RvD1 and TRPA1 blockers. Thus, we hypothesize a dysequillibrium in the pro- and antinociceptive machinery in inflammatory pain.

15 February 2016 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
HKHashem Khanbabaei
Hashem Khanbabaei
ATAli Teimoori
Ali Teimoori
MMMilad Mohammadi
Milad Mohammadi